with chemotherapy and targeted therapy, but we don't know how to kill the cells that are not growing fast, and that’s been really hard to study these dormant cells. But what Ahmed has done here is ...

but researchers still seek tips and tricks for optimizing their complex organoid disease models. By monitoring organoids in real time, scientists can ensure their cells are healthy and that their ...

Organoids are made to model human organs and are promising for research and therapy, but there are limitations to their ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer ...

Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist pharma Endocyte looks to have been justified. The big Swiss ...

AAV vector evaluation in vitro for retinal gene therapy Retinal organoids from Newcells have demonstrated the ability to serve as an instructive in vitro model for assessing novel retinal gene ...

In 2025, the therapeutic landscape for advanced prostate cancer in Germany is marked by remarkable progress—ranging from radioligand ... therapy, and advanced hormonal treatments. He’s also involved ...

Novartis already sells one radioligand therapy – Lutathera (177Lu- oxodotreotide) for neuroendocrine tumours – which made $475 million last year, but Pluvicto has the potential to be a bigger ...

Blue Earth Therapeutics’s injectable investigational radioligand therapy, Lutetium rhPSMA-10.1, has led to higher doses of ...

Radioligand therapy is a type of precision nuclear medicine used to treat advanced cancer patients. Radioligand therapy, also known as radionuclide or radiopharmaceutical therapy, is a type of cancer ...